Zai Lab announces updates on China NRDL

Zai Lab announced that the 2023 National Reimbursement Drug List, or NRDL, released by China’s National Healthcare Security Administration, or NHSA, has been updated to include the following medicines and indications: Vyvgart is included for the first time in the NRDL for the treatment of adult patients with generalized myasthenia gravis, or gMG, who are anti-acetylcholine receptor, or AChR, antibody positive; Nuzyra is included for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia, or CABP, and acute bacterial skin and skin structure infections, or ABSSSI and Zejula is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer.